Trial Profile
A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Tegoprazan (Primary) ; Lansoprazole
- Indications Gastric ulcer; Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors CJ HealthCare; HK inno.N
- 23 Jul 2020 Primary endpoint (Cumulative healing rate of gastric ulcer at 8-week) has been met, according to results published in the Alimentary Pharmacology and Therapeutics
- 23 Jul 2020 Results published in the Alimentary Pharmacology and Therapeutics
- 20 Aug 2019 Status changed from recruiting to completed.